A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Inclusion Criteria:

1. Male or female 18 years of age or older.

2. Histologically confirmed diagnosis of solid tumour for which no effective therapy is
available or that is unresponsive to conventional therapy.

3. Meet laboratory parameter requirements at study entry.

Exclusion Criteria:

1. Chemotherapy, radiotherapy, biologic therapy, immunotherapy or any other
investigational drugs within 21 days of beginning study treatment with LOR-253 HCl.

2. A hematologic malignancy.

3. A history of brain or other central nervous system metastases.

4. Have a presence of a significant infection.

5. Clinically significant autoimmune disease.

6. Uncontrolled intercurrent illness.

7. With iron or copper overload syndromes.

8. Pregnancy or breast feeding.